{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Subject diagnosed with diverticulitis', 'Subject has a confirmed active TB.', 'Subject has a positive IGRA result or repeated indeterminate IGRA results during the', 'study, unless active TB is ruled out and the Medical Monitor confirms that study', 'treatment can be resumed as described below:', '- Subjects may resume the administration of study treatment if active TB is ruled out', 'by a certified TB specialist or pulmonologist who is familiar with treating TB (as', 'acceptable per local practice). The subject must also start prophylactic LTBI therapy', 'according to country-specific/CDC guidelines (see Appendix 4 [Section 13.4]) and', 'agree to complete the entire course of recommended LTBI therapy. Study treatment', 'should not be administered until active TB is ruled out and the subject starts LTBI', 'therapy.', 'Subject has a severe or life-threatening infection that requires hospitalization.', 'Subject has a malignancy (with the exception of local and resected basal or squamous', 'cell carcinoma of the skin), after confirmation with the Medical Monitor.', '6.12 Blinding', 'This is an open-label study. The subjects, Investigators, study site staff, and Sponsor will not', 'be blinded.', 'An independent CVAC and DSMB will be established for this study to assess safety on an', 'ongoing basis (see Section 7.4.4). Members of the CVAC will be blinded to treatment group.', 'Members of the DSMB will be partially blinded to treatment group: they will be aware of', 'which subjects are in the same treatment group, but they will not be aware of the treatment', 'assigned to each group. However, members of the DSMB may be unblinded in the event that', 'safety monitoring identifies an issue that needs to be addressed at the treatment group level', '(see Section 7.4.8).', '6.13 Prior and Concomitant Treatments', 'For the first 12 weeks of the OLE study (i.e., through Visit 4 [Week 36]), background', 'therapy requirements (ie, concomitant treatment with MTX and with permitted rescue', 'medication(s) prescribed in the core studies) are detailed in Section 6.1.', 'Concomitant treatment with folic acid >5 mg per week or equivalent is required for all', 'subjects.', 'Other specifically allowed medications are discussed in Section 6.13.2.', 'Amendment 2: 06 March 2019', '84', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Specific treatments prohibited during the course of the study are described in Table 3. Other', 'medications and non-drug therapies not listed within Table 3 that are considered necessary', \"for the subject's safety and well-being may be given at the discretion of the Investigator and\", 'recorded in the appropriate sections of the eCRF. Doses, route of applications, duration of', 'treatment, and reasons for prescription are also to be recorded.', 'A caution regarding cytochrome P (CYP) and transporter proteins is discussed in', 'Section 6.13.1.', 'Table 3', 'Prohibited Medications', 'Treatment', 'Restriction', 'cDMARDs other than MTX', 'Treatment with cDMARDs other than MTX, including leflunomide, is', 'prohibited during the entire study, with the exception of sulfasalazine', 'and/or hydroxychloroquine if they were assigned as rescue medication', 'during the core study.', 'During the first 12 weeks of the OLE study (i.e., up to Visit 4', '[Week 36]), cDMARD background therapy (MTX for all subjects;', 'sulfasalazine and/or hydroxychloroquine for subjects assigned', 'rescue medication in the core studies) should remain unchanged and', 'may be adjusted only for safety reasons according to Investigator', 'discretion. Subjects from CL04041025 are exempt from this', 'restriction.', 'After the first 12 weeks of the OLE study (i.e., after Visit 4', \"[Week 36]), dose modifications of a subject's existing background\", 'cDMARD therapy are permitted, if deemed appropriate by the', 'Investigator, per local guidelines (see Section 6.13.3). Subjects that', 'did not receive sulfasalazine and/or hydroxychloroquine in the core', 'studies should not be assigned these medications in the OLE study.', 'bDMARDs/kinase inhibitors', 'Treatment with bDMARDs or kinase inhibitors is prohibited during the', 'entire study.', 'Corticosteroids', 'During the first 12 weeks of the OLE study (i.e., up to Visit 4', '[Week 36]):', 'The use of parenteral corticosteroids (with the exception of IA', 'corticosteroids) is prohibited.', 'The use of oral corticosteroids >10 mg/day prednisone or equivalent', 'is prohibited. Dose tapering is permitted according to', 'Investigator discretion; other changes in dose are prohibited', 'unless the Investigator changes the dose for safety reasons.', 'After the first 12 weeks of the OLE study (i.e., after Visit 4 [Week 36]),', 'a change in the route of administration of corticosteroids or a dose', 'adjustment of oral corticosteroids is permitted, including transient dose', 'increases with dose tapering as soon as possible after the dose increase', '(see Section 6.13.3), per Investigator discretion and local practice.', 'Amendment 2: 06 March 2019', '85', 'Confidential']\n\n###\n\n", "completion": "END"}